Abstract：【Objective】To investigate the expression of PI3K/AKT/mTOR signaling pathway and clinical efficacy of different Neoadjuvant Chemotherapy administration (Paclitaxel+Cisplatin) for advanced cervical cancer. 【Methods】From March 2016 to March 2018, 68 patients with advanced cervical cancer who received neoadjuvant chemotherapy in Boai Hospital of Zhongshan City were selected. According to the random table method, they were divided into the interventional group (neoadjuvant interventional arterial chemotherapy) and the intravenous group (neoadjuvant intravenous chemotherapy), with 34 cases in each group. The levels of p-PI3K, p-Akt, p-mTOR, matrix metalloprotease 2 (MMP2) and vascular endothelial growth factor (VEGF) were compared between the two groups. The short-term efficacy and adverse reactions were recorded and compared as well. 【Results】The effective rate of the intervention group was higher than that of the intravenous group, and the incidence of adverse reactions was lower than that of the intravenous group (P<0.05). The levels of p-PI3K, p-Akt, p-mTOR, MMP2 and VEGF protein in cervical cancer tissues of intervention group were significantly lower than those of venous group (P<0.05). 【Conclusion】The short-term efficacy of neoadjuvant interventional arterial chemotherapy for advanced cervical cancer treatment is better than neoadjuvant intravenous chemotherapy. It can effectively inhibit the PI3K/AKT/mTOR signaling pathway in cervical cancer cells, which may be related to the significant inhibition of its phosphorylation.
2019, Vol. 36 
